Cellular and Molecular Mechanisms of Intestinal Fibrosis

키워드

참고문헌 (198)

1. Wynn TA, "Mechanisms of fibrosis : therapeutic translation for fibrotic disease", Nat Med, 18, pp.1028~1040 (2012)
2. Henderson NC, "Fibrosis : from mechanisms to medicines", Nature, 587, pp.555~566 (2020)
3. Weiskirchen R, "Organ and tissue fibrosis : molecular signals, cellular mechanisms and translational implications", Mol Aspects Med, 65, pp.2~15 (2019)
4. Rieder F, "An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease", Aliment Pharmacol Ther, 48, pp.347~357 (2018)
5. Rieder F, "Crohn's disease complicated by strictures : a systematic review", Gut, 62, pp.1072~1084 (2013)
6. Gumaste V, "Benign and malignant colorectal strictures in ulcerative colitis", Gut, 33, pp.938~941 (1992)
7. Chang JT, "Pathophysiology of inflammatory bowel diseases", N Engl J Med, 383, pp.2652~2664 (2020)
8. Rieder F, "Mechanisms, management, and treatment of fibrosis in patients with inflammatory bowel diseases", Gastroenterology, 152, pp.340~350 (2017)
9. Louis E, "Behaviour of Crohn's disease according to the Vienna classification : changing pattern over the course of the disease", Gut, 49, pp.777~782 (2001)
10. Gordon IO, "Fibrosis in ulcerative colitis : mechanisms, features, and consequences of a neglected problem", Inflamm Bowel Dis, 20, pp.2198~2206 (2014)
11. Baumgart DC, "Newer biologic and small-molecule therapies for inflammatory bowel disease", N Engl J Med, 385, pp.1302~1315 (2021)
12. D'Alessio S, "Revisiting fibrosis in inflammatory bowel disease : the gut thickens", Nat Rev Gastroenterol Hepatol, 19, pp.169~184 (2022)
13. Wang J, "Novel mechanisms and clinical trial endpoints in intestinal fibrosis", Immunol Rev, 302, pp.211~227 (2021)
14. Herrera J, "Extracellular matrix as a driver of progressive fibrosis", J Clin Invest, 128, pp.45~53 (2018)
15. Bochaton-Piallat ML, "The myofibroblast in wound healing and fibrosis : answered and unanswered questions", F1000Res, 5(F1000 Faculty Rev), pp.752~ (2016)
16. Davidson S, "Fibroblasts as immune regulators in infection, inflammation and cancer", Nat Rev Immunol, 21, pp.704~717 (2021)
17. West NR, "Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease", Nat Med, 23, pp.579~589 (2017)
18. Rock JR, "Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition", Proc Natl Acad Sci U S A, 108, pp.E1475~E1483 (2011)
19. LeBleu VS, "Origin and function of myofibroblasts in kidney fibrosis", Nat Med, 19, pp.1047~1053 (2013)
20. Zidar N, "Pathology of fibrosis in Crohn's disease-contribution to understanding its pathogenesis", Front Med(Lausanne), 7, pp.167~ (2020)
21. Driskell RR, "Distinct fibroblast lineages determine dermal architecture in skin development and repair", Nature, 504, pp.277~281 (2013)
22. Wynn TA, "Cellular and molecular mechanisms of fibrosis", J Pathol, 214, pp.199~210 (2008)
23. Krystel-Whittemore M, "Mast cell : a multi-functional master cell", Front Immunol, 6, pp.620~ (2016)
24. Galdiero MR, "Bidirectional mast cell-eosinophil interactions in inflammatory disorders and cancer", Front Med(Lausanne), 4, pp.103~ (2017)
25. D'Urso M, "Mechanical and physical regulation of fibroblast-myofibroblast transition : from cellular mechanoresponse to tissue pathology", Front Bioeng Biotechnol, 8, pp.609653~ (2020)
26. Li GQ, "Celastrol inhibits interleukin-17A-stimulated rheumatoid fibroblast-like synoviocyte migration and invasion through suppression of NF-κBmediated matrix metalloproteinase-9 expression", Int Immunopharmacol, 14, pp.422~431 (2012)
27. Lawrance IC, "Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease", Inflamm Bowel Dis, 7, pp.226~236 (2001)
28. Wohlfahrt T, "PU. 1 controls fibroblast polarization and tissue fibrosis", Nature, 566, pp.344~349 (2019)
29. Muhl L, "Single-cell analysis uncovers fibroblast heterogeneity and criteria for fibroblast and mural cell identification and discrimination", Nat Commun, 11, pp.3953~ (2020)
30. Baum J, "Fibroblasts and myofibroblasts : what are we talking about?", J Cardiovasc Pharmacol, 57, pp.376~379 (2011)
31. Rieder F, "Wound healing and fibrosis in intestinal disease", Gut, 56, pp.130~139 (2007)
32. Lawrance IC, "Cellular and molecular mediators of intestinal fibrosis", J Crohns Colitis, 11, pp.1491~1503 (2017)
33. Rieder F, "Intestinal fibrosis in IBD : a dynamic, multifactorial process", Nat Rev Gastroenterol Hepatol, 6, pp.228~235 (2009)
34. Klingberg F, "The myofibroblast matrix : implications for tissue repair and fibrosis", J Pathol, 229, pp.298~309 (2013)
35. Li C, "The fate of myofibroblasts during the development of fibrosis in Crohn's disease", J Dig Dis, 21, pp.326~331 (2020)
36. Li C, "Increased activation of latent TGF-β1 by αVβ3 in human Crohn's disease and fibrosis in TNBS colitis can be prevented by cilengitide", Inflamm Bowel Dis, 19, pp.2829~2839 (2013)
37. Frangogiannis N, "Transforming growth factor-β in tissue fibrosis", J Exp Med, 217, pp.e20190103~ (2020)
38. de Bruyn JR, "Fibrostenotic phenotype of myofibroblasts in Crohn’s disease is dependent on tissue stiffness and reversed by LOX inhibition", J Crohns Colitis, 12, pp.849~859 (2018)
39. Kobayashi M, "Bioengineering functional smooth muscle with spontaneous rhythmic contraction in vitro", Sci Rep, 8, pp.13544~ (2018)
40. Allahverdian S, "Smooth muscle cell fate and plasticity in atherosclerosis", Cardiovasc Res, 114, pp.540~550 (2018)
41. Severi C, "Contribution of intestinal smooth muscle to Crohn's disease fibrogenesis", Eur J Histochem, 58, pp.2457~ (2014)
42. Ng EK, "Human intestinal epithelial and smooth muscle cells are potent producers of IL-6", Mediators Inflamm, 12, pp.3~8 (2003)
43. Kalluri R, "Epithelial-mesenchymal transition and its implications for fibrosis", J Clin Invest, 112, pp.1776~1784 (2003)
44. Lovisa S, "Role of epithelial-to-mesenchymal transition in inflammatory bowel disease", J Crohns Colitis, 13, pp.659~668 (2019)
45. Di Gregorio J, "The epithelial-tomesenchymal transition as a possible therapeutic target in fibrotic disorders", Front Cell Dev Biol, 8, pp.607483~ (2020)
46. Flier SN, "Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis", J Biol Chem, 285, pp.20202~20212 (2010)
47. Bataille F, "Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease", Inflamm Bowel Dis, 14, pp.1514~1527 (2008)
48. Ortiz-Masià D, "WNT2b activates epithelial-mesenchymal transition through FZD4 : relevance in penetrating Crohn´s disease", J Crohns Colitis, 14, pp.230~239 (2020)
49. Iwano M, "Evidence that fibroblasts derive from epithelium during tissue fibrosis", J Clin Invest, 110, pp.341~350 (2002)
50. Frid MG, "Mature vascular endothelium can give rise to smooth muscle cells via endothelialmesenchymal transdifferentiation : in vitro analysis", Circ Res, 90, pp.1189~1196 (2002)
51. Zhang Y, "Endothelial to mesenchymal transition contributes to arsenic-trioxide-induced cardiac fibrosis", Sci Rep, 6, pp.33787~ (2016)
52. Rieder F, "Inflammation-induced endothelial-to-mesenchymal transition : a novel mechanism of intestinal fibrosis", Am J Pathol, 179, pp.2660~2673 (2011)
53. Santamaria PG, "EMT : present and future in clinical oncology", Mol Oncol, 11, pp.718~738 (2017)
54. Vannucchi MG, "Telocytes express PDGFRα in the human gastrointestinal tract", J Cell Mol Med, 17, pp.1099~1108 (2013)
55. Milia AF, "Telocytes in Crohn's disease", J Cell Mol Med, 17, pp.1525~1536 (2013)
56. Ibba-Manneschi L, "Telocyte implications in human pathology : an overview", Semin Cell Dev Biol, 55, pp.62~69 (2016)
57. Wollheim FA, "Telocytes, communicators in healthy stroma and relation to inflammation and fibrosis", Joint Bone Spine, 83, pp.615~618 (2016)
58. Manetti M, "Telocytes are reduced during fibrotic remodelling of the colonic wall in ulcerative colitis", J Cell Mol Med, 19, pp.62~73 (2015)
59. Sahebally SM, "Circulating fibrocytes and Crohn's disease", Br J Surg, 100, pp.1549~1556 (2013)
60. Mifflin RC, "Intestinal myofibroblasts : targets for stem cell therapy", Am J Physiol Gastrointest Liver Physiol, 300, pp.G684~G696 (2011)
61. Sazuka S, "Fibrocytes are involved in inflammation as well as fibrosis in the pathogenesis of Crohn's disease", Dig Dis Sci, 59, pp.760~768 (2014)
62. Grieb G, "Circulating fibrocytes : biology and mechanisms in wound healing and scar formation", Int Rev Cell Mol Biol, 291, pp.1~19 (2011)
63. Ueno A, "Association of circulating fibrocytes with fibrostenotic small bowel Crohn's disease", Inflamm Bowel Dis, 28, pp.246~258 (2022)
64. Kuroda N, "Infiltrating CCR2+monocytes and their progenies, fibrocytes, contribute to colon fibrosis by inhibiting collagen degradation through the production of TIMP-1", Sci Rep, 9, pp.8568~ (2019)
65. Friedrich M, "Cytokine networks in the pathophysiology of inflammatory bowel disease", Immunity, 50, pp.992~1006 (2019)
66. Gieseck RL 3rd, "Type 2 immunity in tissue repair and fibrosis", Nat Rev Immunol, 18, pp.62~76 (2018)
67. Pelly VS, "IL-4-producing ILC2s are required for the differentiation of TH2 cells following Heligmosomoides polygyrus infection", Mucosal Immunol, 9, pp.1407~1417 (2016)
68. Gibbs BF, "Purified human peripheral blood basophils release interleukin-13 and preformed interleukin-4 following immunological activation", Eur J Immunol, 26, pp.2493~2498 (1996)
69. Symowski C, "Th2 cell-derived IL-4", IL-13promote ILC2 accumulation in the lung by ILC2-intrinsic STAT6 signaling in mice, 2019, pp.49, 1421~1432
70. Gordon S, "Alternative activation of macrophages : mechanism and functions", Immunity, 32, pp.593~604 (2010)
71. Barron L, "Fibrosis is regulated by Th2 and Th17responses and by dynamic interactions between fibroblasts and macrophages", Am J Physiol Gastrointest Liver Physiol, 300, pp.G723~G728 (2011)
72. Wynn TA, "Fibrotic disease and the T(H)1", T(H)2 paradigm, 2004, pp.4, 583~594
73. Maher TM, "Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis", Eur Respir J, 57, pp.1902442~ (2021)
74. Raghu G, "SAR156597 in idiopathic pulmonary fibrosis : a phase 2 placebo-controlled study(DRI11772)", Eur Respir J, 52, pp.1801130~ (2018)
75. Raghu G, "A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis", N Engl J Med, 350, pp.125~133 (2004)
76. Allanore Y, "A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-ofconcept study of romilkimab(SAR156597)in early diffuse cutaneous systemic sclerosis", Ann Rheum Dis, 79, pp.1600~1607 (2020)
77. Wynn TA, "Macrophages in tissue repair, regeneration, and fibrosis", Immunity, 44, pp.450~462 (2016)
78. Cosín-Roger J, "The activation of Wnt signaling by a STAT6-dependent macrophage phenotype promotes mucosal repair in murine IBD", Mucosal Immunol, 9, pp.986~998 (2016)
79. Dharmasiri S, "Human intestinal macrophages are involved in the pathology of both ulcerative colitis and Crohn disease", Inflamm Bowel Dis, 27, pp.1641~1652 (2021)
80. Salvador P, "CD16+ macrophages mediate fibrosis in inflammatory bowel disease", J Crohns Colitis, 12, pp.589~599 (2018)
81. Nayar S, "A myeloid-stromal niche and gp130 rescue in NOD2-driven Crohn's disease", Nature, 593, pp.275~281 (2021)
82. Aran D, "Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage", Nat Immunol, 20, pp.163~172 (2019)
83. Patel DD, "Th17 cell pathway in human immunity : lessons from genetics and therapeutic interventions", Immunity, 43, pp.1040~1051 (2015)
84. Ramani K, "Interleukin-17 : friend or foe in organ fibrosis", Cytokine, 120, pp.282~288 (2019)
85. Biancheri P, "The role of interleukin 17 in Crohn's disease-associated intestinal fibrosis", Fibrogenesis Tissue Repair, 6, pp.13~ (2013)
86. Honzawa Y, "Involvement of interleukin-17A-induced expression of heat shock protein 47in intestinal fibrosis in Crohn's disease", Gut, 63, pp.1902~1912 (2014)
87. Brockmann L, "Regulation of TH17 cells and associated cytokines in wound healing, tissue regeneration, and carcinogenesis", Int J Mol Sci, 18, pp.1033~ (2017)
88. Paul J, "IL-17-driven intestinal fibrosis is inhibited by Itch-mediated ubiquitination of HIC-5", Mucosal Immunol, 11, pp.427~436 (2018)
89. Zhang HJ, "IL-17A promotes initiation and development of intestinal fibrosis through EMT", Dig Dis Sci, 63, pp.2898~2909 (2018)
90. Li J, "Role of interleukin-17 in pathogenesis of intestinal fibrosis in mice", Dig Dis Sci, 65, pp.1971~1979 (2020)
91. Hueber W, "Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease : unexpected results of a randomised, double-blind placebo-controlled trial", Gut, 61, pp.1693~1700 (2012)
92. Targan SR, "A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease", Am J Gastroenterol, 111, pp.1599~1607 (2016)
93. McGee HM, "IL-22 promotes fibroblast-mediated wound repair in the skin", J Invest Dermatol, 133, pp.1321~1329 (2013)
94. Liang SC, "Interleukin(IL)-22and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides", J Exp Med, 203, pp.2271~2279 (2006)
95. Klose CS, "Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis", Nat Immunol, 17, pp.765~774 (2016)
96. Eberl G, "Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology", Science, 348, pp.aaa6566~ (2015)
97. Klose C, "Differentiation of type 1ILCs from a common progenitor to all helper-like innate lymphoid cell lineages", Cell, 157, pp.340~356 (2014)
98. Kabata H, "The group 2 innate lymphoid cell(ILC2)regulatory network and its underlying mechanisms", Immunol Rev, 286, pp.37~52 (2018)
99. Gladiator A, "Cutting edge : IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection", J Immunol, 190, pp.521~525 (2013)
100. Zheng Y, "Interleukin-22mediates early host defense against attaching and effacing bacterial pathogens", Nat Med, 14, pp.282~289 (2008)
101. Messing M, "Group 2 innate lymphoid cells : central players in a recurring theme of repair and regeneration", Int J Mol Sci, 21, pp.1350~ (2020)
102. Forkel M, "Distinct alterations in the composition of mucosal innate lymphoid cells in newly diagnosed and established Crohn’s disease and ulcerative colitis", J Crohns Colitis, 13, pp.67~78 (2019)
103. Lo BC, "The orphan nuclear receptor RORα and group 3 innate lymphoid cells drive fibrosis in a mouse model of Crohn's disease", Sci Immunol, 1, pp.eaaf8864~ (2016)
104. Scarpa M, "The epithelial danger signal IL-1α is a potent activator of fibroblasts and reactivator of intestinal inflammation", Am J Pathol, 185, pp.1624~1637 (2015)
105. Drygiannakis I, "Proinflammatory cytokines induce crosstalk between colonic epithelial cells and subepithelial myofibroblasts : implication in intestinal fibrosis", J Crohns Colitis, 7, pp.286~300 (2013)
106. Okuno T, "Interleukin-1beta and tumor necrosis factor-alpha induce chemokine and matrix metalloproteinase gene expression in human colonic subepithelial myofibroblasts", Scand J Gastroenterol, 37, pp.317~324 (2002)
107. Andoh A, "Interleukin(IL)-4 and IL-17 synergistically stimulate IL-6 secretion in human colonic myofibroblasts", Int J Mol Med, 10, pp.631~634 (2002)
108. Dohi T, "Mice deficient in Th1-and Th2-type cytokines develop distinct forms of hapten-induced colitis", Gastroenterology, 119, pp.724~733 (2000)
109. Li C, "Noncanonical STAT3 activation regulates excess TGF-β1 and collagen I expression in muscle of stricturing Crohn's disease", J Immunol, 194, pp.3422~3431 (2015)
110. Franzè E, "Cadherin-11 is a regulator of intestinal fibrosis", J Crohns Colitis, 14, pp.406~417 (2020)
111. Li C, "Mechanisms that mediate the development of fibrosis in patients with Crohn's disease", Inflamm Bowel Dis, 20, pp.1250~1258 (2014)
112. Theiss AL, "Growth hormone reduces the severity of fibrosis associated with chronic intestinal inflammation", Gastroenterology, 129, pp.204~219 (2005)
113. Rogler G, "Differential activation of cytokine secretion in primary human colonic fibroblast", myofibroblast cultures, 2001, pp.36, 389~398
114. Lim WW, "Transgenic interleukin 11 expression causes cross-tissue fibro-inflammation and an inflammatory bowel phenotype in mice", PLoS One, 15, pp.e0227505~ (2020)
115. Guan Q, "Targeting IL-12", IL-23by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis, 2011, pp.17, 646~656
116. Guan Q, "Reversing ongoing chronic intestinal inflammation and fibrosis by sustained block of IL-12 and IL-23 using a vaccine in mice", Inflamm Bowel Dis, 24, pp.1941~1952 (2018)
117. Fichtner-Feigl S, "Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2, 4, 6-trinitrobenzene sulfonic acid colitis", J Immunol, 178, pp.5859~5870 (2007)
118. Fichtner-Feigl S, "IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis", Gastroenterology, 135, pp.2003~2013 (2008)
119. Yagi Y, "Inflammatory responses induced by interleukin-17 family members in human colonic subepithelial myofibroblasts", J Gastroenterol, 42, pp.746~753 (2007)
120. Speca S, "Cellular and molecular mechanisms of intestinal fibrosis", World J Gastroenterol, 18, pp.3635~3661 (2012)
121. Monteleone G, "Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21", Gut, 55, pp.1774~1780 (2006)
122. Zenewicz LA, "Innate and adaptive interleukin-22protects mice from inflammatory bowel disease", Immunity, 29, pp.947~957 (2008)
123. Andoh A, "Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts", Gastroenterology, 129, pp.969~984 (2005)
124. Mathur R, "Induction of autophagy in Cx3cr1+ mononuclear cells limits IL-23", IL-22 axismediated intestinal fibrosis, 2019, pp.12, 612~623
125. Borowczyk J, "IL-25(IL-17E)in epithelial immunology and pathophysiology", J Allergy Clin Immunol, 148, pp.40~52 (2021)
126. Wang AJ, "Genetic deletion of IL-25(IL-17E)confers resistance to dextran sulfate sodium-induced colitis in mice", Cell Biosci, 4, pp.72~ (2014)
127. Imai J, "Flagellin-mediated activation of IL-33-ST2 signaling by a pathobiont promotes intestinal fibrosis", Mucosal Immunol, 12, pp.632~643 (2019)
128. Kotsiou OS, "IL-33", ST2axis in organ fibrosis, 2018, pp.9, 2432~
129. Franzè E, "Interleukin-34 stimulates gut fibroblasts to produce collagen synthesis", J Crohns Colitis, 14, pp.1436~1445 (2020)
130. Scheibe K, "Inhibiting interleukin 36 receptor signaling reduces fibrosis in mice with chronic intestinal inflammation", Gastroenterology, 156, pp.1082~1097 (2019)
131. Shih DQ, "Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis", Mucosal Immunol, 7, pp.1492~1503 (2014)
132. Wenxiu J, "Effect and mechanism of TL1A expression on epithelial-mesenchymal transition during chronic colitis-related intestinal fibrosis", Mediators Inflamm, 2021, pp.5927064~ (2021)
133. Ulloa L, "Inhibition of transforming growth factor-beta", SMAD signalling by the interferongamma, Nature, pp.1999, 397[DOI]
134. Leeb SN, "Reduced migration of fibroblasts in inflammatory bowel disease : role of inflammatory mediators and focal adhesion kinase", Gastroenterology, 125, pp.1341~1354 (2003)
135. Francoeur C, "Degeneration of the pericryptal myofibroblast sheath by proinflammatory cytokines in inflammatory bowel diseases", Gastroenterology, 136, pp.268~277 (2009)
136. Kobori A, "Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis", J Gastroenterol, 45, pp.999~1007 (2010)
137. Lopetuso LR, "IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair", Proc Natl Acad Sci U S A, 115, pp.E9362~E9370 (2018)
138. Masterson JC, "Eosinophils and IL-33 perpetuate chronic inflammation and fibrosis in a pediatric population with stricturing Crohn's ileitis", Inflamm Bowel Dis, 21, pp.2429~2440 (2015)
139. Lu W, "Platelet-derived growth factor C signaling is a potential therapeutic target for radiation proctopathy", Sci Transl Med, 13, pp.eabc2344~ (2021)
140. Takemura N, "Eosinophil depletion suppresses radiation-induced small intestinal fibrosis", Sci Transl Med, 10, pp.eaan0333~ (2018)
141. Walana W, "IL-8 antagonist, CXCL8(3-72)K11R", G31P coupled with probiotic exhibit variably enhanced therapeutic potential in ameliorating ulcerative colitis, 2018, pp.103, 253~261
142. Lenti MV, "Intestinal fibrosis", Mol Aspects Med, 65, pp.100~109 (2019)
143. Cook SA, "Hiding in plain sight : interleukin-11emerges as a master regulator of fibrosis, tissue integrity, and stromal inflammation", Annu Rev Med, 71, pp.263~276 (2020)
144. Ng B, "Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis", Sci Transl Med, 11, pp.eaaw1237~ (2019)
145. Schafer S, "IL-11 is a crucial determinant of cardiovascular fibrosis", Nature, 552, pp.110~115 (2017)
146. Martin JC, "Single-cell analysis of Crohn’s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy", Cell, 178, pp.1493~1508 (2019)
147. Schmitz J, "IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines", Immunity, 23, pp.479~490 (2005)
148. Lopetuso LR, "Emerging role of the interleukin(IL)-33", ST2 axis in gut mucosal wound healing and fibrosis, 2012, pp.5, 18~
149. Morimoto Y, "Amphiregulinproducing pathogenic memory T helper 2 cells instruct eosinophils to secrete osteopontin and facilitate airway fibrosis", Immunity, 49, pp.134~150 (2018)
150. Baghdadi M, "Interleukin-34, a comprehensive review", J Leukoc Biol, 104, pp.931~951 (2018)
151. Preisser L, "IL-34and macrophage colony-stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells", Hepatology, 60, pp.1879~1890 (2014)
152. Baek JH, "IL-34 mediates acute kidney injury and worsens subsequent chronic kidney disease", J Clin Invest, 125, pp.3198~3214 (2015)
153. Franzè E, "Interleukin-34sustains inflammatory pathways in the gut", Clin Sci(Lond), 129, pp.271~280 (2015)
154. Zwicker S, "Interleukin 34: a new modulator of human and experimental inflammatory bowel disease", Clin Sci(Lond), 129, pp.281~290 (2015)
155. Hwang SJ, "Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis", Arthritis Res Ther, 14, pp.R14~ (2012)
156. Mantovani A, "Interleukin-1 and related cytokines in the regulation of inflammation and immunity", Immunity, 50, pp.778~795 (2019)
157. Elias M, "IL-36 in chronic inflammation and fibrosis: bridging the gap?", J Clin Invest, 131, pp.e144336~ (2021)
158. Nishida A, "Increased expression of interleukin-36, a member of the interleukin-1 cytokine family, in inflammatory bowel disease", Inflamm Bowel Dis, 22, pp.303~314 (2016)
159. Scheibe K, "IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo", Gut, 66, pp.823~838 (2017)
160. Takahashi K, "Interleukin(IL)-1βis a strong inducer of IL-36γ expression in human colonic myofibroblasts", PLoS One, 10, pp.e0138423~ (2015)
161. Migone TS, "TL1A is a TNF-like ligand for DR3 and TR6", DcR3 and functions as a T cell costimulator, 2002, pp.16, 479~492
162. Valatas V, "TL1A(TNFSF15)and DR3(TNFRSF25) : a co-stimulatory system of cytokines with diverse functions in gut mucosal immunity", Front Immunol, 10, pp.583~ (2019)
163. Takedatsu H, "TL1A(TNFSF15)regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation", Gastroenterology, 135, pp.552~567 (2008)
164. Jacob N, "Direct signaling of TL1A-DR3 on fibroblasts induces intestinal fibrosis in vivo", Sci Rep, 10, pp.18189~ (2020)
165. Li H, "TL1A blocking ameliorates intestinal fibrosis in the T cell transfer model of chronic colitis in mice", Pathol Res Pract, 214, pp.217~227 (2018)
166. Barrett R, "Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis", Am J Pathol, 180, pp.636~649 (2012)
167. Yang DH, "TNFSF15 is an independent predictor for the development of Crohn's disease-related complications in Koreans", J Crohns Colitis, 8, pp.1315~1326 (2014)
168. Shih DQ, "Constitutive TL1A(TNFSF15)expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis", PLoS One, 6, pp.e16090~ (2011)
169. Clarke AW, "An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease", MAbs, 10, pp.664~677 (2018)
170. Jacob N, "Inflammation-independent TL1A-mediated intestinal fibrosis is dependent on the gut microbiome", Mucosal Immunol, 11, pp.1466~1476 (2018)
171. Hassan-Zahraee M, "Antitumor necrosis factor-like ligand 1A therapy targets tissue inflammation and fibrosis pathways and reduces gut pathobionts in ulcerative colitis", Inflamm Bowel Dis, 28, pp.434~446 (2022)
172. Li J, "Pathogenesis of fibrostenosing Crohn's disease", Transl Res, 209, pp.39~54 (2019)
173. Bos S, "Metabolic modulation during intestinal fibrosis", J Dig Dis, 21, pp.319~325 (2020)
174. Latella G, "Results of the 4th scientific workshop of the ECCO(I) : pathophysiology of intestinal fibrosis in IBD", J Crohns Colitis, 8, pp.1147~1165 (2014)
175. Derkacz A, "The role of extracellular matrix components in inflammatory bowel diseases", J Clin Med, 10, pp.1122~ (2021)
176. Soroosh A, "Crohn's disease fibroblasts overproduce the novel protein KIAA1199 to create proinflammatory hyaluronan fragments", Cell Mol Gastroenterol Hepatol, 2, pp.358~368 (2016)
177. Wight TN, "The extracellular matrix: an active or passive player in fibrosis?", Am J Physiol Gastrointest Liver Physiol, 301, pp.G950~G955 (2011)
178. Flynn RS, "Endogenous IGF-I and alphaVbeta3 integrin ligands regulate increased smooth muscle hyperplasia in stricturing Crohn's disease", Gastroenterology, 138, pp.285~293 (2010)
179. Sheehan AL, "Fat-wrapping in Crohn's disease : pathological basis and relevance to surgical practice", Br J Surg, 79, pp.955~958 (1992)
180. Borley NR, "The relationship between inflammatory and serosal connective tissue changes in ileal Crohn's disease : evidence for a possible causative link", J Pathol, 190, pp.196~202 (2000)
181. Liu Q, "Constrictive and hypertrophic strictures in ileal Crohn's disease", Clin Gastroenterol Hepatol, 20, pp.e1292~e1304 (2022)
182. Coffey CJ, "Inclusion of the mesentery in ileocolic resection for Crohn's disease is associated with reduced surgical recurrence", J Crohns Colitis, 12, pp.1139~1150 (2018)
183. Ha C, "Translocation of viable gut microbiota to mesenteric adipose drives formation of creeping fat in humans", Cell, 183, pp.666~683 (2020)
184. Mao R, "A positive feedback loop between creeping fat and intestinal stricture formation in Crohn's disease : the role of creeping fat-derived free fatty acids, extracellular matrix, and integrin", Gastroenterology, 158, pp.S-188~S-189 (2020)
185. Mao R, "Creeping-fat derived free fatty acids induce hyperplasia of intestinal muscularis propria muscle cells : a novel link between fat and intestinal stricture formation in Crohn's disease", Gastroenterology, 154, pp.S-131~ (2018)
186. Mao R, "Activated intestinal muscle cells promote preadipocyte migration : a novel mechanism for creeping fat formation in Crohn's disease", Gut, 71, pp.55~67 (2022)
187. Bauer-Rowe KE, "Where there is fat there is fibrosis : elucidating the mechanisms of creeping fatdriven stricture formation", J Am Coll Surg, 233, pp.S65~ (2021)
188. Xiong S, "Reverse translation approach generates a signature of penetrating fibrosis in Crohn's disease that is associated with anti-TNF response", Gut, 71, pp.1289~1301 (2022)
189. Bauer-Rowe KE, "A Surgical model for investigating the role of creeping fat in intestinal fibrosis", J Am Coll Surg, 231, pp.S50~S51 (2020)
190. Rieder F, "The gut microbiome in intestinal fibrosis : environmental protector or provocateur?", Sci Transl Med, 5, pp.190ps10~ (2013)
191. Darfeuille-Michaud A, "High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease", Gastroenterology, 127, pp.412~421 (2004)
192. Zorzi F, "Pathogenic aspects and therapeutic avenues of intestinal fibrosis in Crohn's disease", Clin Sci(Lond), 129, pp.1107~1113 (2015)
193. Sugiura H, "Activation of Tolllike receptor 3 augments myofibroblast differentiation", Am J Respir Cell Mol Biol, 40, pp.654~662 (2009)
194. Bhattacharyya S, "Pharmacological inhibition of Toll-like receptor-4 signaling by TAK242 prevents and induces regression of experimental organ fibrosis", Front Immunol, 9, pp.2434~ (2018)
195. Yang R, "Toll-like receptor 4 contributes to a myofibroblast phenotype in cardiac fibroblasts and is associated with autophagy after myocardial infarction in a mouse model", Atherosclerosis, 279, pp.23~31 (2018)
196. Macias-Ceja DC, "Succinate receptor mediates intestinal inflammation and fibrosis", Mucosal Immunol, 12, pp.178~187 (2019)
197. Di Gregorio J, "Role of glycogen synthase kinase-3β and PPAR-γ on epithelial-to-mesenchymal transition in DSS-induced colorectal fibrosis", PLoS One, 12, pp.e0171093~ (2017)
198. Mao R, "The mesenteric fat and intestinal muscle interface : creeping fat influencing stricture formation in Crohn's disease", Inflamm Bowel Dis, 25, pp.421~426 (2019)

관련 논문AI추천